Bristol-Myers Squibb Co.’s research-and-development chief will leave the company later this year after the drugmaker completes its $74 billion acquisition of rival Celgene Corp. and will hand over his responsibilities to a pair of scientists from outside the company. Thomas Lynch Jr., Bristol’s chief scientific officer overseeing R&D since March 2017, is scheduled to leave in October, the company said Wednesday in unveiling its management team when the deal closes.

Source: Wall Street Journal June 05, 2019 11:05 UTC